Evelyn Ellis-Grosse, PhD

Chief Scientific Officer

Evelyn Ellis-Grosse, PhD, currently serves as chief scientific officer of Zavante Therapeutics and has worked in clinical research and therapeutic drug development for more than 20 years. Ellis-Grosse co-founded Zavante Therapeutics in 2013, serving as president and chief executive officer until 2015. Dr. Ellis-Grosse previously held positions of increasing responsibility at Wyeth (Pfizer), including AVP and director of the global division of anti-infective clinical research and development. In this capacity, she defined and implemented strategic goals and priorities for the infectious disease therapeutic franchise, was responsible for scientific and operational planning, and management and execution of multiple global drug development programs.  In 2006, she formed e2g Biopharmaceutical Consulting, providing global drug development advice to pharmaceutical clients and venture capital firms. She is co-inventor of three patents, a reviewer for several peer-reviewed journals and a member of the editorial board for Antimicrobial Agents and Chemotherapeutics. Dr. Ellis-Grosse authored and co-authored over 90 peer-reviewed scientific publications, presentations and book chapters. She received her bachelor’s degree in biology from Judson College and a doctorate in pharmaceutics from Auburn University.  Dr. Ellis-Grosse is a 2006 national award recipient of the “Hero of Chemistry” award from the American Chemical Society for her leadership in the clinical development of TYGACIL® (Tigecycline), and a 2010 recipient of Honorary Doctorate of Humane Letters from Judson College.